SCHEDULE: Intracoastal Capital Discloses 9.99% Stake in Purple Biotech

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Purple Biotech Ltd. through a warrant.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Purple Biotech Ltd.
• The Reporting Persons beneficially own 200,453,695 Ordinary Shares of Purple Biotech Ltd., representing 9.99% of the class.
• This ownership is primarily derived from shares issuable upon the exercise of a warrant held by Intracoastal Capital LLC (the "Intracoastal Warrant").
• The Intracoastal Warrant includes a blocker provision, which prevents its exercise to the extent that it would result in the holder's beneficial ownership exceeding 9.99% of the Ordinary Shares.
• Without this blocker provision, the Reporting Persons would have been deemed to beneficially own 400,000,000 Ordinary Shares.
• The calculation of the 9.99% ownership is based on 1,806,089,800 Ordinary Shares outstanding as of September 16, 2025, as reported by Purple Biotech Ltd., plus the 200,453,695 Ordinary Shares issuable upon exercise of the Intracoastal Warrant.

Sentiment

Score: 6

Explanation: The filing is neutral in tone as it is a factual disclosure of beneficial ownership. The significant stake by an institutional investor could be seen as a positive signal, but it does not provide operational or financial performance details of Purple Biotech Ltd.

Positives

• A significant institutional investor group has taken a substantial stake, potentially signaling confidence in Purple Biotech Ltd.'s future prospects.
• The inclusion of a 'blocker provision' in the warrant demonstrates a strategic approach to ownership, avoiding immediate triggers for higher regulatory disclosure thresholds (e.g., 10% ownership).

Future Outlook

NA

Industry Context

This filing indicates a significant investment by a capital group in a biotech company, which is common in the sector given the high capital requirements and potential for substantial returns from successful drug development. Such a stake can be viewed as a vote of confidence in the company's long-term potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could influence investor perception and potentially the share price. The blocker provision in the warrant limits immediate dilution risk from its exercise.
• Company Management: Awareness of a large, active shareholder group holding a substantial stake.

Key Dates

Recommendation

This Schedule 13G filing indicates that Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, holds a significant 9.99% beneficial ownership in Purple Biotech Ltd. through a warrant. While the presence of a substantial institutional investor can be a positive signal, this filing alone does not provide sufficient operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The 'blocker provision' in the warrant limits immediate dilution risk by preventing ownership from exceeding 9.99%. Investors should 'hold' and await further financial disclosures or strategic updates from Purple Biotech Ltd. to make a more informed decision.

Keywords

Purple Biotech Ltd., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Warrant, Biotech, Equity Stake, SEC Filing